TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10990237
Drug: Hydrocortisone (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (13 mg/m2 every morning and 3 mg/m2 every afternoon for 12 weeks)
Study: 8649699
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of vitamin B6
Study: 3579005
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered theophylline
Study: 3579005
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inhaled salbutamol and orally administered theophylline
Study: 1348010
Drug: Prednisolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (20 mg)
Study: 31962050
Drug: Cervarix and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervarix and Gardasil (HPV vaccines)
Study: 31255678
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (absent depression)
Study: 30580340
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg thrice daily
Study: 30580340
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (Control)
Study: 25952634
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus gliclazide modified release combination therapy
Study: 25952634
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin monotherapy
Study: 23498848
Drug: SYN1 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN1 (0.8 g/dL Orafti®Synergy1) supplemented infant formula
Study: 16278686
Drug: DHA-rich algae
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich algae oil (2.14 g of DHA/day)
Study: 16278686
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (6 g)
Study: 11519638
Drug: Chronic nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic nicotine treatment
Study: 11519638
Drug: Acute nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute nicotine treatment
Study: 7965876
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% 2-6 ml/h infusion through a catheter placed in the sciatic or posterior tibial nerve sheath
Study: 7965876
Drug: Bupivacaine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine treatment
Study: 3662562
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate in optimized vehicle (ointment)
Study: 17211115
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil group (aromatherapy with lavender, ylangylang, and bergamot, once daily for 4 weeks)
Study: 12845429
Drug: 30 mmol
Normalized name: Dextrose/Potassium Phosphate 5%-30 MMOLE Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mmol potassium phosphate in 50 ml saline over 2 h (Group 1)
Study: 12845429
Drug: 30 mmol
Normalized name: Dextrose/Potassium Phosphate 5%-30 MMOLE Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mmol potassium phosphate in 100 ml saline over 4 h (Group 2)
Study: 12845429
Drug: 45 mmol
Normalized name: dibasic potassium phosphate 45 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mmol potassium phosphate in 100 ml saline over 3 h (Group 3)
Study: 12845429
Drug: 45 mmol
Normalized name: dibasic potassium phosphate 45 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mmol potassium phosphate in 100 ml saline over 6 h (Group 4)
Study: 11282702
Drug: Four-session interpersonal-therapy-oriented
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-session interpersonal-therapy-oriented group intervention
Study: 11282702
Drug: Treatment-as-usual condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual condition
Study: 9250849
Drug: Phenobarbital (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (10 mg/kg body weight, intravenous, followed by maintenance doses until delivery or 34 weeks gestation)
Study: 9250849
Drug: Placebo (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous, followed by maintenance doses until delivery or 34 weeks gestation)
Study: 28720658
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-90)
Study: 28720658
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2-90)
Study: 23744427
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin (3 g daily in three divided doses)
Study: 16420274
Drug: Canine retraction
Normalized name: CanineAid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canine retraction using 100 g sentalloy springs
Study: 11117374
Drug: Enalapril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10-20 mg) and Verapamil (120-240 mg)
Study: 9315788
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled beta-agonist therapy
Study: 9315788
Drug: As-needed inhaled
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As-needed inhaled beta-agonist therapy
Study: 8157042
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion glucagon
Study: 2872870
Drug: Family treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family treatment
Study: 2872870
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of family treatment and social skills training
Study: 2872870
Drug: Drug-treated condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-treated condition (Control)
Study: 30513795
Drug: High-dose B-group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose B-group vitamin supplementation
Study: 24717247
Drug: Taper (desvenlafaxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper (desvenlafaxine 25 mg/d)
Study: 24717247
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation (placebo)
Study: 24717247
Drug: No discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No discontinuation (desvenlafaxine 50 mg/d)
Study: 20445353
Drug: Combined immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunotherapy treatment with rIL-2 and IFN-alpha
Study: 20445353
Drug: NHL patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHL patients treated with immunotherapy
Study: 15629825
Drug: 2% gel
Normalized name: SULFUR 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% gel twice daily (gel/gel)
Study: 15629825
Drug: 2% gel
Normalized name: SULFUR 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% gel daily (evening, placebo/gel)
Study: 15629825
Drug: Vehicle twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle twice daily (placebo/placebo)
Study: 11973494
Drug: POM 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: POM 1.0 mg/kg
Study: 11973494
Drug: INM 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: INM 0.4 mg/kg
Study: 11973494
Drug: POD 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: POD 0.5 mg/kg
Study: 7478701
Drug: Ketamine (0-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0-40 mg, i.m., 8 times per day)
Study: 24793536
Drug: FF/VI (fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI (fluticasone furoate/vilanterol), 100/25 µg
Study: 24793536
Drug: FF (fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF (fluticasone furoate), 100 µg
Study: 19953771
Drug: Whitestrips (strips,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitestrips (strips, twice a day, 30 minutes each for two weeks)
Study: 3281764
Drug: Indomethacin (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.35 mg.kg‐1 bolus followed by 0.07 mg.kg‐1.hr‐1 infusion for 24 hr)
Study: 25076278
Drug: Ylang ylang
Normalized name: ylang-ylang oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ylang ylang essential oil by inhalation
Study: 23332981
Drug: Reduced injection
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced injection frequency
Study: 23332981
Drug: Concurrent decreased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent decreased drug injection and increased alcohol consumption
Study: 19450093
Drug: High-dosage medical
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage medical exercise therapy (HD)
Study: 19450093
Drug: Low-dosage medical
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage medical exercise therapy (LD)
Study: 16686385
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 2% lidocaine and adrenaline 1:200,000 (group I)
Study: 16686385
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of 1% lidocaine and adrenaline 1:400,000 (group II)
Study: 16686385
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of 1% lidocaine and adrenaline 1:200,000 (group III)
Study: 16686385
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of 1% lidocaine (group IV)
Study: 12839378
Drug: Triple therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy: lansoprazole 30 mg twice daily, amoxycillin 500 mg four times daily, clarithromycin 500 mg twice a day for 10 days
Study: 12839378
Drug: Quadruple therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy: tri-potassium dicitrato bismuthate 120 mg four times daily, metronidazole 400 mg thrice daily, tetracycline 500 mg four times daily for 10 days
Study: 10791133
Drug: Albuterol plus
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol plus prednisolone
Study: 10791133
Drug: Albuterol plus
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol plus placebo
Study: 29668448
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of tranexamic acid per kg (group A)
Study: 24726066
Drug: Home-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based occupational therapy for 10 weeks according to national practice guidelines
Study: 24726066
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with no occupational therapy
Study: 23610854
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% with sufentanil 0.5 microg/ml (group 1)
Study: 23610854
Drug: Ropivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.125% with sufentanil 0.5 microg/ml (group 2)
Study: 23610854
Drug: Levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.125% with sufentanil 0.5 microg/ml (group 3)
Study: 20491746
Drug: PN 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN 400 containing 30 mg esomeprazole
Study: 20491746
Drug: PN 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN 400 containing 20 mg esomeprazole
Study: 20491746
Drug: PN 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN 400 containing 10 mg esomeprazole
Study: 20491746
Drug: Naproxen plus
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen plus esomeprazole 20 mg
Study: 17564755
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg retarded release levodopa/carbidopa
Study: 17564755
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg levodopa/carbidopa/entacapone
Study: 10607255
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 125 mg (n = 15)
Study: 10607255
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 125 mg
Study: 7829789
Drug: Cilazapril 1
Normalized name: cilazapril 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 1 mg twice daily
Study: 7829789
Drug: Cilazapril 5
Normalized name: cilazapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5 mg twice daily
Study: 7829789
Drug: Cilazapril 10
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 10 mg twice daily
Study: 79764
Drug: Polyvalent pseudomonas
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent pseudomonas vaccine
Study: 30538070
Drug: IN Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN Ketamine (1 ml = 50 mg)
Study: 30538070
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline, 1 ml)
Study: 22926087
Drug: Fatigue assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatigue assessment using the subscale of the Checklist Individual Strength, assessed monthly between T2 and T3.
Study: 22926087
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for postcancer fatigue, aimed at the fatigue-perpetuating factors, could be offered from two months after successful cancer treatment.
Study: 21977863
Drug: Fluoxetine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (n = 40)
Study: 19700194
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg at baseline and months 1, 3, and 5)
Study: 19700194
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ranibizumab (0.5 mg) and focal/grid laser (at baseline and month 3)
Study: 19700194
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ranibizumab and focal/grid laser
Study: 9404431
Drug: Monotherapy in
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy in the 80 mmHg target group
Study: 8453217
Drug: Elective red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective red cell transfusion to maintain capillary haematocrit greater than 0.35 l/1 (group 1)
Study: 3705896
Drug: Naloxone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4 mg) mixed with 10 ml of orange juice
Study: 3705896
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline mixed with 10 ml of orange juice
Study: 19194534
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (highest tertile risk)
Study: 10430114
Drug: Accelerated titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated titration regimen of sotalol (80 mg every 6 hours for four doses, then 160 mg every 12 hours for nine doses)
Study: 10430114
Drug: Standard titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard titration regimen of sotalol (80 mg every 6 hours for eight doses, then 160 mg every 12 hours for nine doses)
Study: 7756495
Drug: Cefazolin (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1-g intravenous dose)
Study: 7756495
Drug: Cefotetan (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (1-g intravenous dose)
Study: 2405040
Drug: Furosemide (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (approximately 28 mg) administered by inhalation
Study: 6947990
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment (instruction and practice in oral hygiene techniques and meticulous prophylaxis) repeated every 2-3 months
Study: 27684425
Drug: Oral colostrum
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral colostrum priming (OCP)
Study: 27684425
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral colostrum priming (Control)
Study: 7837153
Drug: Antibody to
Normalized name: Antibody to HPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody to purified 38-kDa protein of M. tuberculosis
Study: 7837153
Drug: Antibody to
Normalized name: Antibody to HPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody to 65-kDa HSP of M. leprae
Study: 25049140
Drug: Behavioural activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural activation treatment (up to 12 sessions)
Study: 22652535
Drug: Extended daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended daily diafiltration (EDDF)
Study: 20524719
Drug: rosuvastatin/fenofibric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin/fenofibric acid 20 mg/135 mg
Study: 20524719
Drug: rosuvastatin/fenofibric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin/fenofibric acid 10 mg/135 mg
Study: 20524719
Drug: rosuvastatin/fenofibric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin/fenofibric acid 5 mg/135 mg
Study: 12209085
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance medications
Study: 12209085
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily symptom code and use of albuterol for asthma symptoms
Study: 12209085
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily symptom code and daily use of albuterol
Study: 7565455
Drug: HOSS Ca
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOSS Ca (900 mg Ca/day)
Study: 7565455
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (900 mg Ca/day)
Study: 6156321
Drug: Prostaglandin A1
Normalized name: Prostaglandin A1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin A1 (PGA1) infusion at 1/microgram/kg/min during water loading
Study: 6156321
Drug: Prostaglandin A1
Normalized name: Prostaglandin A1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin A1 (PGA1) infusion at 1/microgram/kg/min during water deprivation
Study: 6156321
Drug: Prostaglandin A1
Normalized name: Prostaglandin A1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin A1 (PGA1) infusion with hypertonic mannitol during water deprivation
Study: 30277455
Drug: Supplemental Cr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental Cr (0.05 mg Cr as Cr-methionine/kg of BW0.75)
Study: 17504894
Drug: Pramlintide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (up to 240 microg, self-administered via sc injection three times a day for 16 weeks)
Study: 9842252
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2% eye drops, one drop each eye, four times daily for 8 weeks
Study: 2775153
Drug: Individual cognitive‐behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive‐behaviour therapy (ICBT)
Study: 2775153
Drug: Group cognitive‐behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive‐behaviour therapy (GCBT)
Study: 2775153
Drug: Individual cognitive‐behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive‐behaviour therapy (ICBT) vs Group cognitive‐behaviour therapy (GCBT)
Study: 799975
Drug: Diftalone 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diftalone 500 mg per day
Study: 24838782
Drug: Congruence Couple
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congruence Couple Therapy (CCT) for 12 weeks
Study: 23062489
Drug: Sitagliptin (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (50mg daily for 3 months)
Study: 21320954
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (ET)
Study: 18664712
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg of methylphenidate
Study: 10757456
Drug: cold solution
Normalized name: All-Nite Cold Solution
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cold solution (2-3 degrees C)
Study: 10757456
Drug: hot solution
Normalized name: Goody's Headache Relief Shot Solution (Berry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hot solution (55-58 degrees C)
Study: 10757456
Drug: room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: room temperature solution (20-21 degrees C)
Study: 10757456
Drug: lactose solution
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose solution (50 g)
Study: 9351617
Drug: Colchicine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.6 mg twice a day)
Study: 1609547
Drug: CVD 908
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 908 Salmonella typhi vaccine strain (5 x 10(7) organisms with sodium bicarbonate)